Procedural Advantages of a Novel Drug-Eluting Coronary Stent

University Hospital Heidelberg814 enrolled

Overview

This study sought to compare procedural performance of a new coronary stent generation, that is already available in Germany, with hitherto established current drug-eluting stents.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

814

Conditions

Coronary Artery Disease

Interventions

Synergy StentDEVICE

Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.

Currently common drug-eluting stent (DES)DEVICE

Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * CAD for PCI, consecutive patients Exclusion Criteria: * Age under 18 * Bare Metal Stents or Scaffolds

Outcomes

Primary Outcomes

In-hospital major cardiac adverse events

In-hospital major cardiac adverse events were collected up to one week after procedure throughout the in-patients stay

Time frame: One week post-procedure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.